Drug Trial Radar · NCT00554918
Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy
Last checked: Nov 19, 2026Latest source record: Aug 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 2005
Primary completion
Dec 2008
Study completion Jun 2013
Sponsor
- Lead sponsor
- University Hospital BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 7, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Zoledronic acid may help relieve some of the symptoms caused by bone metastases. Radioactive substances, such as strontium chloride Sr 89, may help relieve bone pain caused by prostate cancer. Giving docetaxel together with prednisolone with or without zoledronic acid and/or strontium chloride Sr 89 may kill more tumor cells. PURPOSE: This randomized phase II trial is studying the side effects and how well giving docetaxel together with prednisolone works with or without zoledronic acid and/or strontium chloride Sr 89 in treating patients with prostate cancer metastatic to bone that has not responded to hormone therapy.
Conditions
- Metastatic Cancer
- Prostate Cancer
Interventions
docetaxelDrug
prednisoloneDrug
zoledronic acidDrug
quality-of-life assessmentProcedure
strontium chloride Sr 89Radiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety
- Toxicity and tolerability of docetaxel and zoledronic acid
- Toxicity and tolerability of docetaxel and strontium chloride Sr 89
- Toxicity and tolerability of docetaxel, zoledronic acid, and strontium chloride Sr 89
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust
Birmingham, England, United Kingdom
Gloucestershire Oncology Centre at Cheltenham General Hospital
Cheltenham, England, United Kingdom
Gloucestershire Royal Hospital
Gloucester, England, United Kingdom
Ipswich Hospital
Ipswich, England, United Kingdom
Mid Kent Oncology Centre at Maidstone Hospital
Maidstone, England, United Kingdom
Christie Hospital
Manchester, England, United Kingdom
Royal Marsden - Surrey
Sutton, England, United Kingdom
Walsall Manor Hospital
Walsall, England, United Kingdom
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom
Ayr Hospital
Ayr, Scotland, United Kingdom
Edinburgh Cancer Centre at Western General Hospital
Edinburgh, Scotland, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
Crosshouse Hospital
Kilmarnock, Scotland, United Kingdom
Wishaw General Hospital
Wishaw, Scotland, United Kingdom
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, United Kingdom
Glan Clwyd Hospital
Rhyl, Denbighshire, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.